Comparative Pharmacology
Head-to-head clinical analysis: IBU TAB 200 versus ORUDIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBU TAB 200 versus ORUDIS.
IBU-TAB 200 vs ORUDIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to anti-inflammatory, analgesic, and antipyretic effects.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day for nonprescription use.
Oral: 50 mg three times daily or 75 mg twice daily; maximum 300 mg/day. Topical: Apply 2-4 g of gel or cream to affected area four times daily. Intramuscular: 50-100 mg every 4-6 hours; maximum 200 mg/day.
None Documented
None Documented
2-4 hours (terminal half-life). Short half-life requires frequent dosing for sustained analgesic/antipyretic effect.
Terminal half-life: ~1.5-2 hours for immediate-release; 30-50% increase in elderly due to reduced clearance. Clinical context: short half-life requires frequent dosing for sustained analgesia; no accumulation with q6-8h dosing.
Renal: 90% as metabolites (glucuronides, hydroxylated derivatives), <10% unchanged. Fecal: <5%.
Renal: ~60% as metabolites (glucuronides of ketoprofen and hydroxylated metabolites); fecal: ~30% (biliary excretion); unchanged drug: <1% in urine.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)